Accepted for Publication: July 27, 2020.
Corresponding Author: Jay F. Piccirillo, MD, Department of Otolaryngology–Head and Neck Surgery, Washington University School of Medicine in St Louis, 660 S Euclid Ave, Campus Box 8115, St Louis, MO 63110 (firstname.lastname@example.org).
Published Online: September 17, 2020. doi:10.1001/jamaoto.2020.3025
Author Contributions: Dr Piccirillo had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Peterson, Lee, Kallogjeri, Chakinala, Piccirillo.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Peterson, Chakinala, Piccirillo.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Peterson, Kallogjeri.
Obtained funding: Peterson, Piccirillo.
Administrative, technical, or material support: Peterson, Lee.
Supervision: Lee, Chakinala, Piccirillo.
Conflict of Interest Disclosures: Dr Piccirillo reported receiving grants from the National Institutes of Health, the Foundation at Barnes-Jewish Hospital, and the Washington University Institute of Clinical and Translational Sciences during the conduct of the study. Mr Peterson reported receiving a stipend from the National Center for Advancing Translational Sciences of the National Institutes of Health during the conduct of the study. Dr Kallogjeri reported owning stock from and serving as consultant for PotentiaMetrics outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported in part by the STAR Award (00752; Dr Piccirillo) from the Washington University Institute of Clinical and Translational Sciences (UL1TR002345), by the National Center for Advancing Translational Sciences of the National Institutes of Health (TL1TR002344; Dr Piccirillo and Mr Peterson), and by the Foundation for Barnes-Jewish Hospital for the Otolaryngology Surgical Outcomes and Quality Improvement Unit at Barnes-Jewish Hospital Award 154092; Dr Piccirillo).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Dr Piccirillo is Editor and Dr Kallogjeri is Statistics Editor of JAMA Otolaryngology–Head & Neck Surgery, but they were not involved in the editorial review or decision to accept this study for publication.
Data Sharing Statement: See Supplement 2.
Additional Contributions: Sara Kukuljan, BS, RN, helped coordinate institutional review board approval of the protocol for the project; Marianne Clancy, RDH, MPA, Nicole Schaefer, BS, and the whole Cure Hereditary Hemorrhagic Telangiectasia team helped in recruitment and reaching out to the Hereditary Hemorrhagic Telangiectasia online community; Scott E. Olitsky, MD, reviewed and promoted the conception and design of the trial; and Jason Jerusik, PharmD, Advanced Rx, served as the research pharmacist. No compensation was given to those acknowledged, and the study team has received written permission to include them in the acknowledgments.
Additional Information: All information and materials in the manuscript are original. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
SD , Boulet
SL , Grant
AM , Hulihan
MM , Faughnan
ME . The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia. Genet Med
. 2014;16(1):33-39. doi:10.1038/gim.2013.66
KJ , Sautter
NB , McWilliams
et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA
. 2016;316(9):943-951. doi:10.1001/jama.2016.11724
M , Blau
H , Bruckheimer
E , Zur
E , Goldschmidt
N . Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia—a preliminary report. J Otolaryngol Head Neck Surg
. 2017;46(1):58. doi:10.1186/s40463-017-0235-x
S , Martín de Rosales Cabrera
AM , Usarralde Pérez
et al. Sclerotherapy and topical nasal propranolol: an effective and safe therapy for HHT-epistaxis. Laryngoscope
. 2019;129(10):2216-2223. doi:10.1002/lary.27930
A , Rai
S , Mcleod
RWJ , Birchall
JC , Elhassan
HA . Topical propranolol for infantile haemangiomas: a systematic review. J Eur Acad Dermatol Venereol
. 2018;32(12):2083-2089. doi:10.1111/jdv.14963
V , Recio-Poveda
L , Zarrabeitia
R , Bernabéu
C , Botella
LM . Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb Haemost
. 2012;108(1):41-53. doi:10.1160/TH11-11-0809
K , Kikuchi
H , Imayoshi
S , Dias
MS . Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia. Auris Nasus Larynx
. 2016;43(4):429-432. doi:10.1016/j.anl.2015.12.001
N , Brilliant
MH , Vidaillet
H . Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep
. 2014;2014:bcr2013203056. doi:10.1136/bcr-2013-203056PubMed
S , Pitiot
V , Bergerot
et al. Efficacy of timolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Sci Rep
. 2019;9(1):11986. doi:10.1038/s41598-019-48502-9
AV , Lonkar
SL , Deshkar
SS , Shirolkar
SV , Deshpande
AD . Nasal mucoadhesive in situ gel of ondansetron hydrochloride. Indian J Pharm Sci
. 2009;71(6):711-713.Google Scholar
J , Targum
SD . The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont)
. 2007;4(7):28-37.PubMedGoogle Scholar